Hantz Financial Services Inc. Acquires 834 Shares of Bio-Techne Co. (NASDAQ:TECH)

Hantz Financial Services Inc. boosted its holdings in Bio-Techne Co. (NASDAQ:TECH) by 6.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 13,960 shares of the biotechnology company’s stock after purchasing an additional 834 shares during the period. Hantz Financial Services Inc.’s holdings in Bio-Techne were worth $1,116,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Empirical Finance LLC increased its position in shares of Bio-Techne by 4.1% in the third quarter. Empirical Finance LLC now owns 4,080 shares of the biotechnology company’s stock valued at $326,000 after acquiring an additional 160 shares during the period. Tokio Marine Asset Management Co. Ltd. increased its position in shares of Bio-Techne by 3.9% in the third quarter. Tokio Marine Asset Management Co. Ltd. now owns 5,333 shares of the biotechnology company’s stock valued at $426,000 after acquiring an additional 200 shares during the period. Northwestern Mutual Wealth Management Co. increased its position in shares of Bio-Techne by 12.0% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 1,917 shares of the biotechnology company’s stock valued at $137,000 after acquiring an additional 205 shares during the period. Mather Group LLC. increased its position in shares of Bio-Techne by 51.5% in the third quarter. Mather Group LLC. now owns 612 shares of the biotechnology company’s stock valued at $49,000 after acquiring an additional 208 shares during the period. Finally, Huntington National Bank increased its position in shares of Bio-Techne by 38.5% during the third quarter. Huntington National Bank now owns 756 shares of the biotechnology company’s stock valued at $60,000 after buying an additional 210 shares during the period. 98.95% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. Benchmark reiterated a “buy” rating and set a $95.00 price target on shares of Bio-Techne in a research report on Tuesday, August 13th. Robert W. Baird boosted their price target on shares of Bio-Techne from $82.00 to $84.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. Royal Bank of Canada reduced their price target on shares of Bio-Techne from $72.00 to $70.00 and set a “sector perform” rating on the stock in a research report on Thursday, August 8th. Scotiabank boosted their price target on shares of Bio-Techne from $83.00 to $88.00 and gave the company a “sector outperform” rating in a research report on Thursday, October 31st. Finally, StockNews.com upgraded shares of Bio-Techne from a “hold” rating to a “buy” rating in a research report on Tuesday, November 12th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $81.78.

Bio-Techne Trading Down 0.0 %

NASDAQ:TECH opened at $75.36 on Monday. Bio-Techne Co. has a one year low of $61.16 and a one year high of $85.57. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.56 and a quick ratio of 3.26. The company’s 50-day simple moving average is $73.57 and its 200 day simple moving average is $74.97. The firm has a market capitalization of $11.97 billion, a P/E ratio of 80.17, a PEG ratio of 5.50 and a beta of 1.28.

Bio-Techne (NASDAQ:TECH) last issued its earnings results on Wednesday, October 30th. The biotechnology company reported $0.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.04. The firm had revenue of $289.46 million for the quarter, compared to the consensus estimate of $280.22 million. Bio-Techne had a net margin of 12.86% and a return on equity of 12.76%. The business’s revenue was up 4.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.35 earnings per share. As a group, analysts forecast that Bio-Techne Co. will post 1.68 EPS for the current fiscal year.

Bio-Techne Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, November 22nd. Stockholders of record on Monday, November 11th were paid a $0.08 dividend. The ex-dividend date of this dividend was Friday, November 8th. This represents a $0.32 annualized dividend and a dividend yield of 0.42%. Bio-Techne’s dividend payout ratio is presently 34.04%.

Bio-Techne Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.